Acute skeletal muscle loss in SARS-CoV-2 infection contributes to poor clinical outcomes in COVID-19 patients.
Amy AttawayNicole WelchDhweeja DasarathyJocelyn Amaya-HughleyAnnette BellarMichelle BiehlSiddharth DugarMarielle P K J EngelenJoe ZeinSrinivasan DasarathyPublished in: Journal of cachexia, sarcopenia and muscle (2022)
In a well-characterized cohort of 95 hospitalized patients with acute COVID-19 and two temporally distinct CT scans, acute sarcopenia, determined by standardized reductions in PM and ESM, was associated with worse clinical outcomes. These data lay the foundation for evaluating dynamic muscle loss as a predictor of clinical outcomes and targeting acute sarcopenia to improve clinical outcomes for COVID-19.
Keyphrases
- skeletal muscle
- liver failure
- sars cov
- respiratory failure
- coronavirus disease
- drug induced
- aortic dissection
- computed tomography
- insulin resistance
- hepatitis b virus
- particulate matter
- heavy metals
- type diabetes
- cancer therapy
- magnetic resonance
- metabolic syndrome
- mechanical ventilation
- positron emission tomography
- big data
- polycyclic aromatic hydrocarbons